Search

Your search keyword '"Schulze, Antje"' showing total 12 results

Search Constraints

Start Over You searched for: Author "Schulze, Antje" Remove constraint Author: "Schulze, Antje" Language english Remove constraint Language: english
12 results on '"Schulze, Antje"'

Search Results

1. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

2. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

3. Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

4. Second State of European Cities Report

5. Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies

6. Prognostic Factors for Overall Survival in Relapsed Acute Myeloid Leukemia

7. Long Term Follow up of the AML97-Study for Patients with AML Older Than 60 Years: A Study of the East German Hematology and Oncology Study Group (OSHO)

8. Increasing The Dose Of AraC In Consolidation Therapy Does Not Lead To Higher Overall Survival Or Improved Relapse Incidence In Patients With AML Over The Age Of 60 Years

9. Early Hematopoietic Cell Transplantation Results in Higher Overall Survival and Leukemia Free Survival Compared to Conventional Chemotherapy in High Risk Acute Myeloid Leukaemia (AML) Patients.

10. Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraCApplication Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival

11. Early Allogenic Transplantation Improves Overall Survival (OS) and Event Free Survival (EFS) Independently of the Applied Chemotherapy in AML Patients with Unfavourable Cytogenetic Karyotype.

12. Granulocyte-Colony-Stimulating Factor (G-CSF) Accelerates Normal Myeloid Recovery More Efficiently in Patients with Favorable Than with Intermediate or Unfavorable Cytogenetic Risk Acute Myeloid Leukemias (AML): A Retrospective Analysis of the East German Hematology Oncology Study Group (OSHO).

Catalog

Books, media, physical & digital resources